LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

May 07, 2025 | Last Trade: US$31.37 0.22 -0.70

EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025.

Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET.  Mr. Hughes will join the “Pros and Cons of Royalty Model – Especially in Current Financing Environment” panel discussion at 4:00 PM ET.  Mr. Sitko will participate in the “Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?” panel at 5:00 PM ET.  Registration for the conference can be accessed by visiting https://ct.to/wD4ms7s.  XOMA Royalty’s presentations can be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  

In addition, members of XOMA Royalty’s business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held on May 20, 2025, in New York, NY.

About XOMA Royalty Corporation

XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

XOMA Investor Contact
Juliane Snowden            
XOMA Royalty  
+1 646-438-9754            
This email address is being protected from spambots. You need JavaScript enabled to view it.      
XOMA Media Contact
Kathy Vincent
KV Consulting & Management
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page